Results 101 to 110 of about 21,434 (231)

Nanoparticles in Vascular Dementia: Advantages and Challenges

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
This review highlights the dual diagnostic and therapeutic potential of nanomaterials in Vascular Dementia (VaD). By effectively crossing the blood–brain barrier, functionalized nanoparticles facilitate early diagnosis by targeting Aβ deposits and vascular lesions.
Xianxin Liu, JiaLi Hu, Yueming qiu, Huaying Wang, Chunxiao Shen, Ziying Liu, Yiting He, Xuefei Du, Xiaorong Zhang   +8 more
wiley   +1 more source

Cognitive performance of healthy young rats following chronic donepezil administration. [PDF]

, 2008
RATIONALE: Experimental studies have investigated the effects of chronic donepezil treatment on the behavioral deficits elicited by reduced activity or the loss of cholinergic neurons that occurs in aging or in models of dementia. However, few studies
Federico, F, Foti F, GELFO, FRANCESCA, Francesca Gelfo, Foti, F, CUTULI, DEBORA, Gelfo F, Cutuli D, Laura Mandolesi, Petrosini L., Bartolo, P. DE, Cutuli, D, MANDOLESI, Laura, FEDERICO, FRANCESCA, Petrosini, L., PETROSINI, Laura, De Bartolo P, FOTI, FRANCESCA IRENE, DE BARTOLO, Paola, Federico F, Mandolesi L   +20 more
core   +1 more source

Inhibitory effect of donepezil on bradykinin-induced increase in the intracellular calcium concentration in cultured cortical astrocytes

Journal of Pharmacological Sciences, 2017
Donepezil is a potent and selective acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease. In the present study, we investigated the responses of astrocytes to bradykinin, an inflammatory mediator, and the effect of donepezil ...
Kouki Makitani, Shota Nakagawa, Yasuhiko Izumi, Akinori Akaike, Toshiaki Kume   +4 more
doaj   +1 more source

Tramiprosate, the Active Agent of ALZ‐801, Modulates Amyloidogenic APP Processing and Tau Phosphorylation in a Cellular Model of Alzheimer's Disease

Drug Development Research, Volume 87, Issue 4, June 2026.
ABSTRACT ALZ‐801, a valine‐conjugated prodrug of tramiprosate, has recently been evaluated in a Phase III trial as a potential Alzheimer's disease (AD)‐modifying therapy. Tramiprosate reduces misfolding of amyloid beta (Aβ) monomers and inhibits oligomer formation. In the present study, we investigated tramiprosate's effects on amyloidogenic processing
Kevser Biberoglu, Ozden Tacal
wiley   +1 more source

Effect of Psychoeducational Intervention on Donepezil Retention Rate and Analysis of Reasons for the Discontinuation in Patients with Alzheimer’s Dementia: A Randomized Study

Patient Preference and Adherence, 2021
Tetsumasa Kamei,1 Hiroyuki Kobayashi,2,3 Maika Nishida,2 Kenzo Muramoto,2 Shohei Nishimoto2 1Shonan Fujisawa Tokushukai Hospital, Kanagawa, Japan; 2Eisai Co., Ltd., Medical Headquarters, Tokyo, Japan; 3Department of Neuropsychiatry, School of Medicine ...
Kamei T, Kobayashi H, Nishida M, Muramoto K, Nishimoto S   +4 more
doaj  

Potential of Aeginetia indica for Alzheimer's Disease Management: In Vitro, In Vivo, and Computational Insights

Food Science &Nutrition, Volume 14, Issue 6, June 2026.
MeOH extract of Aeginetia indica (AİME); chromatographic study: LCMS/MS and GCMS; in vitro assays: AChE assays → ↓ AChE level, ↓ inflammation level and antioxidant assays → ROS; in vivo anti‐inflammatory study: ↓ inflammation level; molecular docking → molecular dynamics simulations: acacetin and acteoside.
Marjanur Rahman Bhuiyan, Md. Sharif Reza, Sadikur Rahman Shuvo, Mustafa Abdullah Yilmaz, Syed Mumtahin Mannan Siam, Md. Shadman Sakib, Oguz Cakir, Md. Nazmul Islam Durjoy, Abbas Tarhan, Nuraniye Eruygur, A. F. M. Shahid Ud Daula   +10 more
wiley   +1 more source

FDA Approval of Donanemab‐azbt: A New Dawn in Alzheimer's Disease Treatment

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Alzheimer's disease (AD) is a neurodegenerative condition marked by the accumulation of beta‐amyloid plaques and neurofibrillary tangles, leading to neuronal death and cognitive decline. Acetylcholinesterase inhibitors (AChEIs) such as donepezil, galantamine, and rivastigmine are commonly used to enhance cognitive function by ...
Rumaisa Riaz, Marrium Fatima, Sadia Ramzan, Diya Rathi, Filzah Fatima, Maha Farooq, Ayesha Shaukat, Nawal Khaliq, Aymar Akilimali   +8 more
wiley   +1 more source

The Role of Magnetic Resonance Spectroscopy (MRS), Diffusion‐Tensor‐Imaging (DTI) and Structural MRI in the Alzheimer's Disease and Mild Cognitive Impairment Diagnosis: A Review

Journal of Magnetic Resonance Imaging, Volume 63, Issue 6, Page 1509-1545, June 2026.
ABSTRACT Alzheimer's disease (AD) is one of the most common neurological disorders affecting older adults, with approximately 7.2 million cases only in the United States. This number is projected to increase to 13.8 million in the United States by 2060, leading to increased expenditures for healthcare, long‐term care and hospice services. Consequently,
Valentina Zecca, Gianmauro Palombelli, Nicola Vanacore, Rossella Canese   +3 more
wiley   +1 more source

Peran donepezil dalam terapi penyakit alzheimer

, 1999
Neurotransmission system impairment is the prominent factor in the pathophysiology of Alzheimer\u27s disease. Neurotransmission is the basis for information processing in the central nervous system.
Samekto Wibowo
core   +1 more source

Comparison of In Silico AChE Inhibitory Potentials of Some Donepezil Analogues

Pharmata
Cholinesterases are important in ensuring hemostasis in our body. Excessive increase in cholinesterase function causes various cholinergic dysfunctions. Alzheimer's is a disease characterized by loss of cholinergic activity, which is especially common in
Mehmet Koca
doaj